

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

NCT04304820

Status	RECRUITING
Phase	Phase 2
Sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (7)

- Age \geq 3 years old
- Weight $>$ 12Kg
- Severe aplastic anemia:
- Bone marrow cellularity $<$ 30% (excluding lymphocytes) AND At least two of the following:
- Absolute neutrophil count $<$ 500/microliter

... and 2 more (see full listing online)

Exclusion (30)

- Known diagnosis or high suspicion of Fanconi anemia or other constitutional marrow failure syndrome
- Evidence of a clonal disorder on cytogenetics performed within 12 weeks of study entry involving chromosome 7 or complex karyotype. Patient will not be excluded if cytogenetics are not done or are pending
- A course of prior immunosuppressive therapy (ATG, cyclosporine, alemtuzumab, and high dose cyclophosphamide), or eltrombopag
- SGOT or SGPT $>$ 2.5 times the upper limit of normal or total bilirubin $>$ 1.5 x upper limit of normal
- Subjects with liver cirrhosis (as determined by the investigator).

... and 25 more (see full listing online)

Locations (1 total)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States